PMID- 17000005
OWN - NLM
STAT- MEDLINE
DCOM- 20070315
LR  - 20151119
IS  - 0163-7258 (Print)
IS  - 0163-7258 (Linking)
VI  - 113
IP  - 1
DP  - 2007 Jan
TI  - Immunoglobulin E: role in asthma and allergic disease: lessons from the clinic.
PG  - 121-33
AB  - The role of immunoglobulin E (IgE) in allergic asthmatic disease is well 
      established. Allergen-specific IgE binds to its cognate receptors, thus 
      triggering a series of cellular events. These events include presentation of 
      antigen by dendritic cells and the degranulation of mast cells and basophils to 
      release numerous factors that play an integral part in potentiating the disease 
      symptoms. Studies in the mouse indicate that a reduction in IgE levels could lead 
      to significant attenuation of the allergic inflammatory response associated with 
      diseases such as asthma, making IgE a target for the development of new 
      therapeutic agents. Omalizumab (Xolair), a recombinant humanised monoclonal 
      anti-IgE antibody that blocks the interaction of IgE with its receptors, is the 
      first anti-IgE agent to undergo clinical development. Several clinical studies 
      have been performed in adults and children with moderate-to-severe allergic 
      asthma to evaluate the efficacy and safety of this agent, but which have also 
      enabled an insight into the role of IgE in human disease. IgE plays a significant 
      role in a number of allergic conditions including allergic rhinitis and allergies 
      to various substances. Recent data suggests that local IgE production may occur 
      in mucosal tissues and that locally significant concentrations of IgE, not 
      reflected by serum IgE concentrations, indicate that it may play a role in 
      non-atopic as well as atopic disease.
FAU - Owen, Charles E
AU  - Owen CE
AD  - Novartis Institutes for Biomedical Research, Wimblehurst Road, Horsham, West 
      Sussex, RH12 5AB, United Kingdom. Charles.Owen@Novartis.Com
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20060925
PL  - England
TA  - Pharmacol Ther
JT  - Pharmacology & therapeutics
JID - 7905840
RN  - 0 (Anti-Allergic Agents)
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Receptors, IgE)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Animals
MH  - Anti-Allergic Agents/*therapeutic use
MH  - Anti-Asthmatic Agents/*therapeutic use
MH  - Antibodies, Anti-Idiotypic
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Asthma/*drug therapy/immunology
MH  - Clinical Trials as Topic/methods
MH  - Humans
MH  - Hypersensitivity/*drug therapy/immunology
MH  - Immunoglobulin E/*immunology
MH  - Omalizumab
MH  - Receptors, IgE/immunology
MH  - Research Design
MH  - Treatment Outcome
RF  - 93
EDAT- 2006/09/27 09:00
MHDA- 2007/03/16 09:00
CRDT- 2006/09/27 09:00
PHST- 2006/07/12 00:00 [received]
PHST- 2006/07/18 00:00 [accepted]
PHST- 2006/09/27 09:00 [pubmed]
PHST- 2007/03/16 09:00 [medline]
PHST- 2006/09/27 09:00 [entrez]
AID - S0163-7258(06)00134-3 [pii]
AID - 10.1016/j.pharmthera.2006.07.003 [doi]
PST - ppublish
SO  - Pharmacol Ther. 2007 Jan;113(1):121-33. doi: 10.1016/j.pharmthera.2006.07.003. 
      Epub 2006 Sep 25.